Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYTOSHRINK: SBRT + Ipilimumab/Nivolumab for Metastatic Kidney Cancer
NCT04090710Phase 2Completed
- Sponsor
- Ontario Clinical Oncology Group
- Start
- Jan 2020
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) (2 arms), sponsored by Ontario Clinical Oncology Group. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2020; status: completed.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04090710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090710.